Breakthrough Male Contraceptive May Temporarily Stop Sperm Production: Research Shows - Video

A birth control breakthrough for men may finally be on the horizon.

Researchers at Cornell University have made a significant breakthrough in the search for a safe, reversible, and long-acting nonhormonal male contraceptive—an innovation long considered the “holy grail” of reproductive health. In a proof-of-principle study conducted in mice and published in Proceedings of the National Academy of Sciences, scientists demonstrated that temporarily interrupting a critical step in sperm production can effectively halt fertility without causing permanent damage.

The team focused on meiosis, the specialized cell division process that produces sperm. Using a small molecule called JQ1 inhibitor, originally developed for cancer research, they disrupted a key stage known as prophase 1. This intervention caused developing sperm cells to stop maturing, effectively shutting down sperm production during treatment.

Importantly, the effect was reversible. Male mice received JQ1 for three weeks, after which sperm production ceased entirely. However, within six weeks of stopping the treatment, normal sperm development resumed. The mice were able to reproduce successfully, and their offspring were healthy, indicating no lasting genetic or reproductive harm.

Unlike hormonal approaches, which can carry side effects and affect broader physiological systems, this method targets the testis directly while preserving spermatogonial stem cells—the foundation of long-term fertility. This ensures that fertility can be restored once treatment stops, addressing a major concern in male contraception research.

Currently, male contraceptive options are limited to condoms and vasectomy, the latter often seen as permanent despite possible reversals. A nonhormonal, reversible method could dramatically expand choices and shift the burden of contraception more evenly.

While JQ1 itself is not suitable for human use due to potential neurological side effects, the study provides a crucial roadmap for developing safer alternatives. Future versions could be delivered as periodic injections or patches, offering men a reliable and convenient contraceptive option.

REFERENCE: Stephanie Tanis, Leah E. Simon, Adriana K. Alexander, Tegan S. Horan, Maria de las Mercedes Carro, Samantha Jane Bonnett, Audrey Xie, Roni Ben-Shlomo, Connor E. Owens, Charles G. Danko, Jelena Lujic, Paula E. Cohen. Meiotic prophase I disruption as a strategy for nonhormonal male contraception using small-molecule inhibitor JQ1. Proceedings of the National Academy of Sciences, 2026; 123 (15) DOI: 10.1073/pnas.2517498123